{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T05:02:25Z","timestamp":1698037345675},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":6775,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1988,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg\/m<jats:sup>2<\/jats:sup> of mitoxantrone given in a 30\u2010minute infusion daily for three days. If the day fourteen bone marrow showed residual leukemia, a second course was given at the same dose for two days. Eight patients (47%) entered complete remission. Three patients (17%) had a partial response, four (24%) did not respond, and two (12%) died with hypoplastic marrows during treatment. Seven of the 12 relapsed patients entered a complete remission, as did one of the five refractory patients. Toxicity was acceptable; prolonged myelosuppression, moderate hepatic toxicity, and stomatitis were the only problems. Several dose schedules of mitoxantrone have been studied by other investigators with varying results. The three\u2010day schedule in the present study is similar to the schedule used for common induction regimens employing anthracycline drugs. On the basis of its activity and acceptable toxicity in relapsed and refractory ANLL patients, we feel that this schedule could be safely combined with other agents in future studies.<\/jats:p>","DOI":"10.1002\/mpo.2950160307","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T17:54:03Z","timestamp":1171994043000},"page":"187-189","source":"Crossref","is-referenced-by-count":1,"title":["Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia"],"prefix":"10.1002","volume":"16","author":[{"given":"James J.","family":"Vredenburgh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. Ross","family":"McLntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Gibbons G.","family":"Cornwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward D.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius J.","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letha E.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"148a","article-title":"Effects of mitoxantrone (dihy\u2010droxyanthracenedione dihydrochloride) in patients with refractory acute leukemia","volume":"58","author":"Paciucci PA","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_3_2","first-page":"3919","article-title":"Mitoxantrone in patients with acute leukemia in relapse","volume":"43","author":"Paciucci PA","year":"1983","journal-title":"Cancer Res"},{"key":"e_1_2_1_4_2","first-page":"41","article-title":"Mitoxantrone in the treatment of relapsed and refractory acute leukemia","volume":"11","author":"Moore J","year":"1984","journal-title":"Sem One"},{"key":"e_1_2_1_5_2","first-page":"389","article-title":"Phase II trial of mitoxantrone in refractory acute leukemia","volume":"67","author":"Estey EH","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_6_2","first-page":"32","article-title":"Mitoxantrone in relapsed and refractory acute leukemia","volume":"11","author":"Prentice HG","year":"1984","journal-title":"Sem One"},{"key":"e_1_2_1_7_2","first-page":"173","article-title":"Two dose schedules of dihydroxyanthracenedione (DHAD) in acute leukemia\u2014a Southwest Oncology Group study","volume":"19","author":"Sakai J","year":"1983","journal-title":"Proc Am Soc ClinOnc"},{"key":"e_1_2_1_8_2","first-page":"1203","article-title":"Treatment of acute myelocytic leukemia: A study by the CALGB","volume":"58","author":"Rai KR","year":"1881","journal-title":"Blood"},{"key":"e_1_2_1_9_2","first-page":"1311","article-title":"Autologous bone marrow transplantation in acute myelogenous leukemia: In vitro treatment with myeloid\u2010specific monoclonal antibodies","volume":"68","author":"Ball ED","year":"1986","journal-title":"Blood"},{"key":"e_1_2_1_10_2","first-page":"221a","article-title":"Sequential Ara\u2010C and mitoxantrone: An effective treatment for refractory and first relapse AML","volume":"68","author":"Cuttner J","year":"1986","journal-title":"Blood"},{"key":"e_1_2_1_11_2","first-page":"224a","article-title":"Mitoxantrone and Vp\u201016 (Nove)\u2014a highly effective and well tolerated regimen for refractory acute myeloid leukemia","volume":"68","author":"Ho AD","year":"1886","journal-title":"Blood"},{"key":"e_1_2_1_12_2","first-page":"608","article-title":"Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II Studies","volume":"71","author":"Mather FJ","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(83)90019-1"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950160307","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950160307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T14:57:59Z","timestamp":1697986679000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950160307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,1]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1988,1]]}},"alternative-id":["10.1002\/mpo.2950160307"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950160307","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,1]]}}}